Background The prognostic significance of myelofibrosis (MF) grade in patients with
myelodysplastic syndrome (MDS) following an allogeneic hematopoietic stem cell …

Purpose Myelofibrosis (MF) may serve as a poor prognostic factor in myelodysplastic
syndromes (MDS). This study explored the impact of allogeneic hematopoietic stem cell …

Allogeneic hematopoietic cell transplantation (AlloHCT) is the only curative approach for
myelofibrosis (MF). However the significant risk of morbidity and mortality associated with …

Therapeutic management of patients with primary or secondary myelofibrosis (MF) who
experience relapse or graft failure following allogeneic haematopoietic cell transplantation …

Purpose The aim of our study was to evaluate the clinical characteristics of myelodysplastic
syndrome (MDS) patients with concomitant mild-to-moderate myelofibrosis (MF), and to …

Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in
myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to …

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for
myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF …

Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative
therapeutic modality for patients with primary or secondary myelofibrosis (MF). However …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …

Allogeneic stem cell transplantation (alloSCT) is the only curative treatment option for
patients with high-risk myelofibrosis (MF). However, it is important to bear in mind that …